Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) bevacizurnab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Wardley, A.
Lohrisch, C.
Joy, A. A.
Young, S.
Yi, F. F.
Marme, A.
Dreosti, L.
Albanell, J.
Munoz, M.
Miles, D. W.
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Hop Reg Sudbury Reg Hosp, Sudbury, ON, Canada
[5] Peking Union Med Coll, Beijing 100021, Peoples R China
[6] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[7] Univ Tubingen, Tubingen, Germany
[8] Univ Pretoria, ZA-0002 Pretoria, South Africa
[9] Hosp del Mar, Barcelona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Vernon Canc Ctr, Middlesex, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116S / 116S
页数：1
相关论文
共 50 条
  • [21] Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
    Liu, Minetta C.
    Hillman, David W.
    Frith, Ashley Elizabeth
    Lyss, Alan P.
    Weckstein, Douglas Jay
    Moreno-Aspitia, Alvaro
    Le-Lindqwister, Nguyet
    Isaacs, Claudine
    Wender, Donald B.
    Lewis, DeQuincy Andrew
    Cole, John T.
    Jaslowski, Anthony John
    Rowland, Kendrith M.
    Openshaw, Thomas H.
    Friday, Bret Edward Buckley
    Fleming, Gini F.
    Asmus, Erik
    Rogak, Lauren J.
    Basch, Ethan M.
    Dueck, Amylou C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) plus trastuzumab (H) plus docetaxel (0) versus Pla plus H plus D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).
    Xu, Binghe
    Li, Wei
    Zhang, Qingyuan
    Shao Zhimin
    Jia, Wang Xiao
    Li, Huiping
    Sun, Tao
    Yin, Yongmei
    Zheng, Hong
    Zhang, Hong
    Chan, Tiffanie
    Lei, Guiyuan
    Restuccia, Eleonora
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    不详
    BREAST CANCER MANAGEMENT, 2013, 2 (04) : 274 - 274
  • [24] AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
    Gianni, Luca
    Romieu, Gilles H.
    Lichinitser, Michail
    Serrano, Sergio V.
    Mansutti, Mauro
    Pivot, Xavier
    Mariani, Paola
    Andre, Fabrice
    Chan, Arlene
    Lipatov, Oleg
    Chan, Stephen
    Wardley, Andrew
    Greil, Richard
    Moore, Nicola
    Prot, Sylvie
    Pallaud, Celine
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1719 - +
  • [25] MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)
    Pierga, J.
    Pritchard, K. I.
    Cortes-Funes, H.
    Biganzoli, L.
    Thomssen, C.
    Franke, F. A.
    Smith, I. E.
    Bogdanova, N.
    Stroyakovskiy, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
    Bisagni, G.
    Musolino, A.
    Panebianco, M.
    De Matteis, A.
    Nuzzo, F.
    Ardizzoni, A.
    Gori, S.
    Gamucci, T.
    Passalacqua, R.
    Gnoni, R.
    Moretti, G.
    Boni, C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1051 - 1057
  • [27] The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer
    G. Bisagni
    A. Musolino
    M. Panebianco
    A. De Matteis
    F. Nuzzo
    A. Ardizzoni
    S. Gori
    T. Gamucci
    R. Passalacqua
    R. Gnoni
    G. Moretti
    C. Boni
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1051 - 1057
  • [28] STRIDE: phase III study of therapeutic cancer vaccine L-BLP25 with hormonal treatment as first-line therapy for women with hormone receptor-positive, inoperable, locally advanced, recurrent, or metastatic breast cancer
    Eiermann, W.
    Miles, D.
    Gilewski, T.
    Trudeau, M.
    Xu, B.
    Barrios, C.
    Pendergrass, K.
    Eggleton, S. P.
    Kashala, O.
    Shulman, L.
    EJC SUPPLEMENTS, 2010, 8 (03): : 87 - 88
  • [29] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
12345